[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymph-node-metastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymph-node-metastasis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,41,77,108,137,161,186,209,239,264,286,310,337,359,388,410,426,448,469,492,521,544,566,587],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100641077","mmr-status-modulates-the-predictive-value-of-lymphatic-invasion-for-lymph-node-metastasis-in-gastric-cancer-100641077",false,"NCT07625735","MMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer","Mismatch Repair (MMR) Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer","Inclusion Criteria:\n\n1. Upfront surgery cohort\n\n   * Patients who underwent radical surgery for gastric cancer at Zhongshan Hospital, Fudan University.\n   * Patients who did not receive neoadjuvant chemotherapy, radiotherapy, immunotherapy, or other antitumor treatments that may affect the pathological assessment of the primary tumor or lymph node metastasis before surgery.\n   * Patients with pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after surgery, including Siewert type II and III tumors only.\n   * Patients with definite pathological assessment of lymphatic invasion and regional lymph node status.\n   * Patients with available and definite MMR status.\n2. ESD cohort\n\n   * Patients who underwent ESD for gastric cancer at Zhongshan Hospital, Fudan University.\n   * Patients with pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma after ESD, including Siewert type II and III tumors only.\n   * Patients with complete post-ESD pathological information, including histological type, depth of invasion, tumor size, ulcerative findings, lymphatic invasion status, venous invasion status, horizontal margin status, and vertical margin status.\n   * Patients with available and definite MMR status.\n\nExclusion Criteria:\n\n1. Upfront surgery cohort\n\n   * Patients with other pathological types, such as gastric squamous cell carcinoma or neuroendocrine carcinoma.\n   * Patients who received neoadjuvant treatment before surgery, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other systemic antitumor treatments.\n   * Patients with missing postoperative pathological information, resulting in inability to determine lymphatic invasion or regional lymph node metastasis status.\n   * Patients with missing or indeterminate MMR status.\n   * Patients with concurrent malignancies that may interfere with the determination of the origin of lymph node metastasis.\n2. ESD cohort\n\n   * Patients with other pathological types, such as gastric squamous cell carcinoma or neuroendocrine carcinoma.\n   * Patients with missing post-ESD pathological information that precludes eCURA classification, eCURA risk score calculation, or assessment of lymphatic invasion status.\n   * Patients with missing or indeterminate MMR status.","ALL","18 Years","95 Years",{"count":20,"type":21},3000,"ESTIMATED","OBSERVATIONAL","Brief Summary\n\nLymph node metastasis (LNM) is a key factor influencing treatment decisions and prognosis in patients with gastric cancer. Lymphatic invasion (LI) is an important pathological predictor of LNM and a core component of the eCURA risk scoring system after endoscopic submucosal dissection (ESD) for early gastric cancer. However, whether LI has the same predictive value for LNM across different mismatch repair (MMR) statuses remains unclear. Compared with proficient mismatch repair (pMMR) gastric cancer, deficient mismatch repair (dMMR) gastric cancer has distinct molecular pathological features and an immune-enriched tumor microenvironment. In early gastric cancer, if LI is associated with a lower LNM risk in dMMR tumors than in pMMR tumors, existing LI-based eCURA risk assessment may overestimate LNM risk in patients with dMMR early gastric cancer and consequently affect decisions regarding additional surgery after ESD. Therefore, this study aims to systematically evaluate the impact of MMR status on the association between LI and LNM using upfront-surgery and post-ESD additional-surgery cohorts from our center, and to explore the potential clinical value of MMR status in refining eCURA-based risk stratification for early gastric cancer.",[25,26,27,28],"Gastric \u002F Gastroesophageal Junction Adenocarcinoma","Mismatch Repair Deficient or MSI-High Solid Tumors","Lymph Node Metastasis","Lymphatic Invasion","NOT_YET_RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-18","ACTUAL",{"date":35,"type":21},"2026-07-01",{"date":37,"type":21},"2027-07-31",{"name":39,"class":40},"Shanghai Zhongshan Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100639876","xr-assisted-petct-navigation-for-cervical-lymph-node-dissection-in-lung-cancer-100639876","NCT07593872","XR-Assisted PET\u002FCT Navigation for Cervical Lymph Node Dissection in Lung Cancer","Application of Extended Reality (XR)-Assisted PET\u002FCT Fusion Navigation in Supraclavicular-to-Cervical Lymph Node Dissection for Lung Cancer","XR-NeckLND","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Confirmed or highly suspected lung cancer with supraclavicular or cervical lymph node metastasis requiring lymph node dissection.\n* Willing to undergo preoperative PET\u002FCT imaging.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Prior high-dose radiation therapy to the neck causing severe distortion of cervical anatomy.\n* Inability to undergo imaging studies, or known allergy to iodinated contrast media.\n* Vulnerable populations as defined by local IRB regulations (e.g., pregnant women, prisoners, individuals lacking decisional capacity).","80 Years",{"count":51,"type":21},10,"INTERVENTIONAL",[54],"NA","This single-arm, prospective feasibility study evaluates an Extended Reality (XR) headset-based preoperative surgical planning workflow that fuses 18F-FDG PET metabolic hotspots with CT anatomy on the OpVerse platform, in patients with non-small cell lung cancer (NSCLC) and supraclavicular or cervical lymph node metastasis (N3 disease) requiring lymph node dissection. Ten participants will undergo standard preoperative contrast-enhanced CT and whole-body PET. Synapse 3D software is used to segment key anatomic structures (clavicle, sternocleidomastoid, internal jugular vein, subclavian vessels, brachial plexus) and to project PET SUV hotspots onto the high-resolution CT model, yielding a patient-specific digital twin of functional tumor boundaries and at-risk neurovascular structures.\n\nImmediately prior to skin incision, the operating surgeon dons an XR head-mounted display (HoloLens via OpVerse) and registers the digital twin to the patient's neck using stable bony landmarks (clavicular head, sternal notch, mastoid). The surgeon plans the optimal incision and initial dissection trajectory, avoiding superficial veins and projecting the location of deep PET-positive nodes. The XR device is then removed, and the planned cervical or supraclavicular lymph node dissection is performed using standard surgical technique without further intraoperative XR guidance.\n\nThe primary endpoint is a composite of safety and feasibility: absence of Grade ≥2 (Clavien-Dindo) phrenic nerve, brachial plexus, chyle leak, Horner syndrome, or major vascular injury through 30 days postoperatively, together with successful XR registration and incision planning. Secondary endpoints include incision planning accuracy, PET hotspot clearance rate, target registration error, operative time, estimated blood loss, and lymph node yield.",[57,27,58],"Non-Small Cell Lung Cancer","Supraclavicular Lymph Node Metastasis",[60,61,62,63,64,65,66,67],"Extended Reality","Augmented Reality","Surgical Navigation","PET\u002FCT Fusion","Image-Guided Surgery","Digital Twin","Lymph Node Dissection","Mixed Reality","2026-05-14",{"date":70,"type":33},"2026-05-18",{"date":72,"type":21},"2026-06-01",{"date":74,"type":21},"2027-04-01",{"name":76,"class":40},"National Taiwan University Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":52,"phases":87,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100552711","phase-3-a-phase-iii-randomised-clinical-trial-of-ultrasound-groin-monitoring-versus-groin-lymph-node-dissection-to-de-escalate-the-extent-of-surgery-in-vulvar-cancer-100552711","NCT06476639","A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer","ANVU","Inclusion Criteria:\n\n* Females, over 18 years, with histologically confirmed SCC or adenocarcinoma of the vulva\n* Clinically stage 1b or 2 on medical imaging (CT or MRI scan of pelvis, abdomen, and chest), without evidence of regional or distant metastatic disease\n* Willing and able to undergo IFL\u002FSNB according to local clinical practice management guidelines\n* Willing and able to comply with all study requirements, timing and\u002For nature of required assessments.\n* Signed written informed consent\n* Negative (serum or urine) pregnancy (BHCG) test ≤ 30 days of surgery ONLY in pre-menopausal women and women \\\u003C 2 years after the onset of menopause.\n\nExclusion Criteria:\n\n* Women with non-invasive vulvar conditions (e.g. non-invasive non-mammary Paget's disease)\n* Clinical or medical imaging evidence of regional and\u002For distant metastatic disease\n* Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)\n* Other prior malignancies \\\u003C5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ\n* Estimated life expectancy of ≤6 months","FEMALE",{"count":86,"type":21},640,[88],"PHASE3","This study is a phase III, open label, multicentre, three-group, randomised clinical trial. The primary aim of this study is to determine whether intensive groin ultrasound monitoring (1) is effective and safe to replace invasive groin lymph node dissection (LND) to manage vulvar cancer, (2) decreases the morbidity associated with vulvar cancer surgery, and (3) is cost effective.",[91,92,27,93,94],"Vulvar Cancer Stage I","Vulvar Cancer Stage II","Groin Node","Ultrasound Therapy; Complications",[96,97],"Vulvar Cancer","Ultrasound Therapy","2026-03-19",{"date":100,"type":33},"2026-03-24",{"date":72,"type":21},{"date":103,"type":21},"2035-12-31",{"name":105,"class":106},"Queensland Centre for Gynaecological Cancer","OTHER_GOV",9,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":52,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100535461","maximizing-lymph-node-dissection-on-fresh-and-fixed-lung-cancer-resection-specimens-100535461","NCT06252129","Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens","Inclusion Criteria:\n\n1. Subjects with a lung nodule or mass who are eligible to undergo a lobectomy.\n2. Subject without any metastasis present.\n3. Subjects who have peripheral lung nodule location\n4. Subjects must be 18 years of age or older.\n\nExclusion Criteria:\n\n1. Subjects who received preoperative chemotherapy or radiotherapy.\n2. Subjects who have a lung nodule located in a central location. Central tumors are defined by those infiltrating the lobar airway.",true,{"count":116,"type":21},160,[54],"Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.",[120,27,121],"Lung Cancer","Pathologic Processes",[123,124,125],"NSCLC","Lymph node dissection","Lung cancer staging","RECRUITING","2026-03-03",{"date":129,"type":33},"2026-03-05",{"date":131,"type":33},"2024-07-26",{"date":133,"type":21},"2027-12",{"name":135,"class":40},"Brigham and Women's Hospital",1,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":52,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},"100536387","node-groin-ultrasound-cancer-100536387","NCT06264167","NODE (groiN ultrasOunD cancEr)","Randomised Feasibility Study of Groin Ultrasound Surveillance to De-Escalate Surgical Intervention in Women With Vulvar Cancer","NODE","Inclusion Criteria:\n\n* Women, over 18 years, with histologically confirmed SCC or adenocarcinoma of the vulva\n* Clinically stage I or II on medical imaging (CT scan of pelvis, abdomen, and chest), without evidence of regional or distant metastatic disease\n* Participant must be suitable to undergo IFL\u002FSNB according to local clinical practice management guidelines\n* Signed written informed consent\n* Negative serum pregnancy test ≤ 30 days of surgery in pre-menopausal women and women \\\u003C 2 years after the onset of menopause\n* Patient lives within 40 km of a medical diagnostic imaging centre (site investigator approval required for special circumstances)\n\nExclusion Criteria:\n\n* Women with non-invasive vulvar conditions (e.g. non-invasive non-mammary Paget's disease)\n* Clinical or medical imaging evidence of regional and\u002For distant metastatic disease\n* Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)\n* Other prior malignancies \\\u003C5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ\n* Estimated life expectancy of ≤6 months",{"count":146,"type":21},30,[54],"This study is an open label, prospective, experimental, randomised clinical trial. The primary aim of this study is to determine whether it is feasible to randomise vulvar cancer patients into one of two treatment arms:1) surgical groin node dissection (as delivered though either a sentinel node biopsy or inguinofemoral lymph node dissection (IFL), or 2) serial high-resolution bilateral groin ultrasound surveillance and clinical examination every 2 months for 12 months.",[150,92,27,93,94],"Vulvar Cancer Stage Ib",[96,97],"2026-02-18",{"date":154,"type":33},"2026-02-20",{"date":156,"type":33},"2024-07-01",{"date":158,"type":21},"2027-12-31",{"name":105,"class":106},5,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":52,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":136},"100594925","molecular-residual-disease-assessment-in-a-representative-diverse-population-of-patients-with-early-stage-breast-cancer-100594925","NCT07025785","Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer","In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.\n\nInclusion Criteria:\n\n1. Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n2. Subjects are willing and able to comply with study procedures based on the judgment of the investigator.\n3. Age ≥ 18 years at time of consent.\n4. Subject must have had surgical intervention and must have sufficient archival specimens from either the primary tumor or a lymph node for ctDNA assay development, as specified in the lab manual.\n\nExclusion Criteria:\n\n1. Subjects must not have had prior neoadjuvant therapy.\n2. Evidence of metastatic disease in imaging.\n3. N1 mic or isolated tumor cells in the lymph nodes",{"count":168,"type":21},100,[54],"The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+\u002FHER2- breast cancer that has spread to 1-3 lymph nodes. Researchers aim to understand if ctDNA detection can identify patients at higher risk of recurrence and guide better treatment decisions. A key aspect is the inclusion of a dedicated cohort of African American\u002FBlack women, a group underrepresented in molecular residual disease (MRD) research despite experiencing more aggressive breast cancers. This study will correlate ctDNA results with treatment patterns (radiotherapy, systemic therapy) and outcomes (recurrence-free and overall survival) in both non-African American and African American participants.",[172,27],"Breast Cancer",[174,175,176],"circulating tumor DNA (ctDNA)","minimal residual disease (MRD)","African American","2026-01-13",{"date":179,"type":33},"2026-01-15",{"date":181,"type":33},"2025-08-22",{"date":183,"type":21},"2027-08",{"name":185,"class":40},"UNC Lineberger Comprehensive Cancer Center",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":52,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":136},"100618178","irreversible-electroporation-for-recurrent-or-metastatic-cervical-lymph-node-metastases-from-thyroid-cancer-a-prospective-multicenter-single-arm-study-100618178","NCT07328243","Irreversible Electroporation for Recurrent or Metastatic Cervical Lymph Node Metastases From Thyroid Cancer: A Prospective Multicenter Single-Arm Study","Efficacy of Irreversible Electroporation Ablation for Postoperative Recurrent or Metastatic Cervical Lymph Node Disease in Thyroid Cancer: A Prospective, Multicenter, Single-Arm, Exploratory Clinical Trial","IRE-TCLN","Inclusion Criteria:1: Voluntarily signs a written informed consent form\n\n2: Age ≥ 18 years at the time of enrollment, male or female.\n\n3: ECOG performance status score of 0 or 1.\n\n4: Expected survival time ≥ 12 months.\n\n5: Cervical lymph node metastases confirmed by pathology (core needle biopsy, fine-needle aspiration biopsy, or thyroglobulin testing in fine-needle aspiration washout fluid), and all of the following: ① Thyroid cancer has recurred\u002Fmetastasized after standard thyroid lobectomy plus lymph node dissection; ② The number of lymph nodes on one side of the neck is ≤ 5, and the maximum long-axis diameter is \\\u003C 3.0 cm.\n\n6: Not suitable for repeat surgical resection or the patient refuses repeat surgery, or \\^131I therapy is ineffective or the patient refuses \\^131I therapy.\n\n7: Adequate organ function as defined below: a) Hematologic (no transfusion of blood components or use of hematopoietic growth factors within 7 days prior to initiation of study treatment): i. Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL (1,500\u002Fmm³); ii. Platelet count (PLT) ≥ 100 × 10\\^9\u002FL (100,000\u002Fmm³); iii. Hemoglobin ≥ 90 g\u002FL. b) Renal: i. Calculated creatinine clearance (CrCl)\\* ≥ 50 mL\u002Fmin. CrCl (mL\u002Fmin) is calculated using the Cockcroft-Gault formula: CrCl (mL\u002Fmin) = {(140 - age) × body weight (kg) × F} \u002F \\[SCr (mg\u002FdL) × 72\\] where F = 1 for males and F = 0.85 for females; SCr = serum creatinine. ii. Urine protein ≤ 2+ (dipstick) or 24-hour urine protein \\\u003C 1.0 g. c) Hepatic: i. Serum total bilirubin (TBil) ≤ 1.5 × ULN (upper limit of normal); for subjects with liver metastases or confirmed\u002Fsuspected Gilbert's syndrome, TBil ≤ 3 × ULN; ii. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; for subjects with liver metastases, AST and ALT ≤ 5 × ULN. d) Coagulation: International normalized ratio (INR), activated partial thromboplastin time (APTT), and prothrombin time (PT) ≤ 1.5 × ULN. e) Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%.\n\n8: Women of childbearing potential must undergo a urine or serum pregnancy test within 3 days prior to the first dose of study treatment (if the urine pregnancy test result cannot be definitively interpreted as negative, a serum pregnancy test must be performed, and the serum result shall prevail), and the result must be negative. If a woman of childbearing potential has sexual intercourse with a male partner who has not been surgically sterilized, she must use an acceptable method of contraception starting from screening and agrees to continue contraception for 180 days after the last dose of the study drug.\n\n9: Male subjects who have not been surgically sterilized and have female partners of childbearing potential must use effective contraception from screening until 180 days after the last dose of the study drug.\n\n10: The subject is willing and able to comply with the visit schedule, treatment regimen, laboratory examinations, and other requirements of the study.\n\n\\-\n\nExclusion Criteria:1: History of severe bleeding tendency or coagulation disorders; presence of clinically significant bleeding within 1 month prior to the first ablation treatment, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing up or expectorating ≥ 1 teaspoon of fresh blood or small clots, or coughing up blood only without sputum; patients with blood-streaked sputum are allowed to be enrolled), or nasal hemorrhage (excluding minor epistaxis and blood-tinged nasal secretions); continuous anticoagulant therapy within 10 days prior to the first administration of study treatment.\n\n2: History of myocarditis, cardiomyopathy, or malignant arrhythmias. Unstable angina, myocardial infarction, congestive heart failure, or vascular disease (such as an aortic aneurysm at risk of rupture) requiring hospitalization within 12 months prior to the first ablation treatment, or other cardiac damage that may affect the safety evaluation of the study device (e.g., poorly controlled arrhythmias, atrial fibrillation, myocardial ischemia\u002Finfarction).\n\n3: Patients who are unable to cooperate with treatment or unable to tolerate general anesthesia.\n\n4: Presence of distant metastases outside the cervical region.\n\n5: Presence of metastatic lymph nodes located in the level VII compartment of the neck.\n\n6: Receipt of \\^131I therapy within the past 6 months.\n\n7: Allergy to ultrasound or CT contrast agents, or inability to undergo contrast-enhanced imaging examinations for other reasons.\n\n8: Patients who have undergone neck surgery, local ablation, chemotherapy, or immunotherapy\u002Ftargeted therapy within the past 3 months.\n\n9: In the opinion of the investigator, ablation needles cannot be safely placed.\n\n10: Presence of metallic implants (plates, screws, etc.) or non-removable implanted catheters in the neck that may affect electric field distribution.\n\n11: Concomitant untreated malignant tumors, or a history of any malignancy within the past 5 years, except for basal cell carcinoma of the skin or carcinoma in situ of the cervix.\n\n12: Concurrent enrollment in another clinical study.\n\n13: Known history of psychiatric disorders, substance abuse, alcoholism, or illicit drug use.\n\n14: Major surgery or severe trauma within 30 days prior to the first ablation treatment, or planned major surgery within 30 days after the first ablation treatment (as determined by the investigator).\n\n15: History within 6 months prior to the first ablation treatment of esophageal or gastric fundal varices, severe peptic ulcer, unhealed wounds, gastrointestinal perforation, enterocutaneous fistula, intestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding; acute exacerbation of chronic obstructive pulmonary disease (COPD) within 1 month prior to the first treatment.\n\n16: Any arterial thromboembolic event, venous thromboembolism of grade ≥ 3 according to CTCAE version 5.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 6 months prior to the first ablation treatment; or current hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg despite oral antihypertensive therapy.\n\n17: Any past or current disease, treatment, or laboratory abnormality that may confound the study results, interfere with the subject's full participation in the study, or make participation not in the subject's best interest.\n\n18: Local or systemic diseases not caused by malignant tumors, or tumor-related secondary diseases or symptoms that may lead to high medical risk and\u002For uncertainty in survival assessment, such as tumor-related leukemoid reaction (white blood cell count \\> 20 × 10\\^9\u002FL), manifestations of cachexia (e.g., known weight loss of more than 10% within 3 months prior to screening), etc.\n\n19: Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.\n\n\\-",{"count":195,"type":21},85,[54],"This is a single-arm, open-label, multicenter, exploratory clinical trial designed to systematically evaluate the efficacy, safety, and patient benefit of ultrasound-guided irreversible electroporation (IRE) ablation for recurrent or metastatic cervical lymph node disease in patients with thyroid cancer after prior curative thyroid surgery and neck dissection. A total of 85 participants will be enrolled.\n\nAfter providing written informed consent, participants will enter a screening period of up to 28 days. During screening, baseline imaging of target lymph nodes will be performed (contrast-enhanced ultrasound or computed tomography), and patient-reported and clinician-reported assessments will be completed, including quality of life, pain, neck appearance, and, when applicable, voice-related outcomes. Laboratory testing and immunology samples will also be collected.\n\nEligible participants will undergo the first IRE ablation on Day 0 under ultrasound guidance. Acute pain will be assessed using the Numeric Rating Scale (NRS) at 0, 4, 8, 24, 48, and 72 hours after the procedure, and all adverse events and device deficiencies will be recorded. The first imaging re-assessment will be performed at Day 30 (±7 days). If residual enhancement suggests incomplete ablation, one salvage IRE ablation may be performed within 14 days. After confirmation of no need for salvage ablation or after completion of salvage ablation, participants will enter follow-up.\n\nFollow-up visits will occur every 3 months starting from Month 3 after the first (or salvage) ablation and will continue until 24 months or until imaging progression, withdrawal, death, or loss to follow-up, whichever occurs first. Imaging assessments will be performed at each follow-up visit. At 12 months, the volume reduction rate (VRR), complete disappearance rate, and recurrence rate of treated lymph nodes will be assessed. Patient-reported outcomes (ThyPRO-39, EQ-5D-5L, neck appearance satisfaction visual analog scale) and clinician-reported scar assessment (Vancouver Scar Scale) will be repeated at Months 1, 3, 6, and 12, with the Voice Handicap Index-10 collected as needed. Laboratory tests (blood count, biochemistry, electrolytes) and immunology samples will be collected every 3 months.\n\nThe primary efficacy endpoint is the lymph node volume reduction rate at 12 months after a single IRE ablation. Secondary efficacy endpoints include 12-month lymph node volume reduction rate after single and\u002For salvage ablation, complete disappearance rate and recurrence rate at 12 months, volume reduction rate at 12 months for lesions located in high-risk anatomical areas, progression-free survival and overall survival, and improvements in quality of life and cosmetic outcomes. Safety endpoints include the incidence of adverse events and serious adverse events graded by NCI CTCAE v5.0, device-related serious adverse events, acute pain tolerability (NRS area under the curve and the proportion of participants with NRS ≥4 of sustained duration), laboratory abnormalities, and changes in voice-related outcomes. Exploratory endpoints include longitudinal changes in immune cell subsets, immune checkpoint and inhibitory molecule expression, and serum cytokine\u002Fchemokine profiles. Adverse events will be followed from the last IRE procedure (including salvage ablation) through 12 months.",[199,27],"Thyroid Cancer Patients","2025-12-26",{"date":202,"type":33},"2026-01-09",{"date":204,"type":33},"2025-12-17",{"date":206,"type":21},"2028-06",{"name":208,"class":40},"Tian'an Jiang",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":52,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100556586","ln-rads-recist-11-and-node-rads-classification-in-the-assessment-of-lymph-nodes-100556586","NCT06527027","LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes","Comparison of the LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes in MRI and CT in Relation to Histopathological Results - a Prospective, Randomised Study","Inclusion Criteria:\n\n* diagnosed or suspected cancer,\n* planned lymph node biopsy or lymphadenectomy,\n* planned or performed CT\u002FMRI covering an area of the body with lymph nodes, - verified histopathologically or cytologically,\n* informed consent to participate in the study.\n\nExclusion Criteria:\n\n* non-diagnostic CT\u002FMRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes,\n* inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant.",{"count":217,"type":21},1000,[54],"The project aims to evaluate the value of the new LN-RADS scales for lymph node classification in CT and MR and to compare this method with two other methods RECIST 1.1 and Node-RADS.\n\nThe main tested system in the study is LN-RADS, the comparators are RECIST 1.1 and Node-RADS criteria.\n\nLymph nodes are a key diagnostic and therapeutic element in oncology. Despite the technological progress, the detection of neoplastic changes in the lymph nodes is of low effectiveness, which results from the imperfection of the criteria used. Currently, the most widely used criterion is the RECIST 1.1 guideline developed in the 1990s, according to which the lymph node dimension in the short axis with a cut-off point of 10 mm is decisive. Lymph nodes smaller than 10 mm across are considered normal. It is a criterion with a high error rate, both due to the false-negative diagnoses (with small metastases below 10 mm) and false-positive diagnoses (in the case of inflammatory lymphadenopathy).\n\nA particular disadvantageous situation is when the metastatic nodes and their transverse dimension is less than 10 mm, because they are treated as healthy nodes and the degree of the disease advancement is underestimated. As a result, the patient is not treated properly - no complete lymphadenectomy, no radiotherapy to the area of these nodes or insufficient systemic treatment. In all cases, underestimating the stage of the neoplastic diseases increases the risk of the recurrence.\n\nLN-RADS accounts small metastases in nodes about 3 mm in size, thus about 20% more metastatic nodes may be detected compared to RECIST 1.1 method. This means that currently, according to RECIST 1.1 rules, approx. 20% of patients have missed nodal metastases and consequently receive insufficient treatment resulting in relapse. Previous studies have shown that RECIST 1.1 shows a high level of underestimation of metastatic nodes. The Node-RADS system, as the second comparator next to RECIT 1.1, is a fairly new system moving towards the structural assessment of lymph nodes, but proposed arbitrarily, without hard evidence for its effectiveness. Despite the publication of the Node-RADS system in a medical journal, it is not validated. The Node-RADS has numerous limitations and weaknesses that reduce its value.",[221,27],"Lymph Node Neoplasm",[223,224,225,226,227,228],"Lymph Nodes","Lymph Node Excision","Tomography, X-ray computed","Lymphadenopathy","Recurrence","Magnetic Resonance Imaging","2025-12-21",{"date":231,"type":33},"2025-12-30",{"date":233,"type":33},"2023-12-01",{"date":235,"type":21},"2028-12-31",{"name":237,"class":40},"Copernicus Memorial Hospital",6,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":248,"conditions":249,"keywords":252,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":136},"100596830","lymph-node-metastasis-in-early-esophageal-squamous-cell-carcinoma-100596830","NCT07050576","Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma","Deep Learning and Radiomics for Prediction of Lymph Node Metastasis in Early-stage Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Patients with pathologically confirmed early-stage (T1) ESCC\n* Preoperative contrast-enhanced CT data within 2 weeks before surgery\n* Without any treatment before surgical resection\n\nExclusion Criteria:\n\n* Patients who underwent neoadjuvant therapy or endoscopic treatment\n* Insufficient CT imaging or poor CT quality\n* Incomplete pathology results\n* Presence of metastatic disease",{"count":247,"type":21},500,"This study aims to develop a predictive model using deep learning and radiomics to assess the likelihood of lymph node metastasis in patients with early-stage esophageal squamous cell carcinoma (ESCC). Lymph node metastasis is a critical factor in determining the treatment approach and prognosis for ESCC patients. By analyzing medical imaging data, we hope to create a non-invasive method that can assist doctors in making more accurate treatment decisions. This research could improve patient outcomes by enabling earlier and more tailored interventions.",[250,27,251],"ESCC","Radiomics",[250,253,254],"Lymph node metastasis","radiomics","2025-06-26",{"date":257,"type":33},"2025-07-03",{"date":259,"type":33},"2024-05-01",{"date":261,"type":21},"2025-11-30",{"name":263,"class":40},"The First Affiliated Hospital of Anhui Medical University",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":52,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":136},"100563873","image-guided-ultrasound-robotic-intraoperative-evaluation-of-lymph-nodes-status-in-gynecological-malignancies-100563873","NCT06621823","Image-guided Ultrasound Robotic Intraoperative Evaluation of Lymph-nodes Status in Gynecological Malignancies","R-LYNUS","Inclusion Criteria:\n\n* Women undergoing robotic surgery for gynecological malignancies (ovarian, endometrial, cervical cencers)\n* Need for nodal excision (staging or cytoreductive reasons)\n* 18-99 years old\n* Absence of contemporary lymphatic diseases\n* Absence of previous oncological disease in the last 5 years\n* Willingness to participate in the study and to provide informed consent\n\nExclusion Criteria:\n\n* \\- Previous radiotherapy treatments in the area of analysed lymph nodes\n* Previous chemotherapy treatments","99 Years",{"count":116,"type":21},[54],"The assessment of lymph node status is of crucial importance in gynaecological malignancies.\n\nIndeed, the prognosis and adjuvant treatment regimens are strongly influenced by the presence of nodal involvement. Systematic extensive lymphadenectomies are often performed for staging, diagnosis of skip metastases and to define the radiation field when radiotherapy treatments are required. Nevertheless, these can lead to significant short-term and long-term lymphatic complications, which are difficult to justify if the lymph nodes are free from metastasis. To avoid unnecessary comprehensive procedures in early-stage cancers, evaluation of the sentinel lymph node has acquired a valuable role even if limitations are still present (rate of frozen section false negative, \"empty packets\" and mapping failure). The introduction of an intra-operative non-invasive imaging technique capable of describing the presence and characteristics of lymph nodes could help in (1) eliminating the risk of empty packet, (2) orienting the intraoperative decision while avoiding the drawbacks of frozen section (time and resources, partial destruction of the tissue material), (3) orientate the pathological section if frozen section is used. To date, technological advancements have paved the way for enhanced intra-operative assessment of cancerous organs and lesions. Over the past decade, the evolution of robotic surgery combined with advancements in image-guided surgery techniques has led to the introduction of ultrasound probes designed specifically for intraoperative ultrasound during robotic surgery (RIOUS). Apart from the conventional rigid laparoscopic probes, which can be inserted through an accessory trocar, there are robotic probes tailored to fit device arms, and drop-in flexible probes that are becoming increasingly relevant in the scientific panorama. Notably, the latter drop-in probes feature a rigid segment designed for compatibility with robotic graspers, leveraging the dexterity and rotational manoeuvrability inherent to robotic surgery. Such probes, already proven effective in evaluating liver and kidney lesions as well as tumour margins, hold promise for intraoperative lymph node assessments due to the possibility of reaching difficult anatomical spaces thanks to the robotic-assisted movements",[27,276],"Gynecologic Cancer","2025-06-11",{"date":279,"type":33},"2025-06-15",{"date":281,"type":33},"2024-07-25",{"date":283,"type":21},"2026-05-31",{"name":285,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":293,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":52,"phases":295,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":136},"100557617","phase-1-pilot-study-of-mpb-2043-enhanced-mri-for-nodal-staging-in-head-and-neck-squamous-cell-carcinomas-100557617","NCT06540443","Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas","A Pilot Feasibility Study of MPB-2043 Enhanced Magnetic Resonance Imaging (MRI) for Nodal Staging in Subjects With Head and Neck Squamous Cell Carcinomas","Inclusion Criteria:\n\n* Subjects aged 20 years and above\n* Subjects with histologically proven head and neck squamous cell carcinomas or with suspicious metastatic lymph nodes (≥ pathological T-stage 1 and 2) without previous treatment by surgery\n* Based on the site's clinical practice, subjects require lymphadenectomy treatment within 8 weeks.\n* Subjects must be nonlactating.\n* Subjects must be able to understand and be willing to sign a written informed consent document.\n* Subjects must be able to comply with the study protocol.\n\nExclusion Criteria:\n\n* Subjects with contraindications to MRI\n* Subjects with a serious allergic history or known allergy to similar ingredients of the study contrast agent (i.e., Gd-based, SPIO particles, and iodinated contrast agents).\n* Subjects obtained gadolinium-enhanced MRI ≤ 7 days before the enrollment.\n* Subjects who participated in another imaging-related clinical trial 30 days prior to the study enrollment.\n* Subjects with active systemic infections, active and clinically significant cardiac diseases, active gastrointestinal ulcers, or medical conditions that may significantly affect action, adequate absorption, and elimination of investigational contrast agent.\n* Subjects with kidney disease or impairment.\n* Subjects with liver or spleen disease or impairment based on other clinical imaging, such as CT or gadolinium contrast MRI, and clinical laboratory results.\n* Subjects with active hepatitis B or hepatitis C infection.\n* Subjects with bone marrow disorders or a history of a bone marrow transplant.","20 Years",{"count":5,"type":21},[296],"PHASE1","This study evaluates the safety and effectiveness of MPB-2043, a superparamagnetic iron oxide (SPIO) contrast agent, for enhancing MRI in detecting metastatic lymph nodes in head and neck cancer. The study compares four doses of MPB-2043 (0.5 mg\u002Fkg, 1 mg\u002Fkg, 2 mg\u002Fkg, and 3 mg\u002Fkg) and assesses the optimal timing for post-dose imaging using T1\u002FT2\u002FT2\\*-weighted sequences to improve the accuracy of nodal staging.",[299,27],"Head and Neck Squamous Cell Carcinoma","2025-05-05",{"date":302,"type":33},"2025-05-08",{"date":304,"type":33},"2024-12-19",{"date":306,"type":21},"2026-09",{"name":308,"class":309},"MegaPro Biomedical Co. Ltd.","INDUSTRY",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":136},"100579811","a-deep-learning-model-for-diagnosing-lymph-node-metastasis-in-nasopharyngeal-carcinomanpc-100579811","NCT06829147","A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)","Development and Validation of a Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma Using Histologic Whole Slide Images and Time-dependent Magnetic Resonance Images","NPC","Inclusion Criteria:\n\n1. The primary lesion was pathologically confirmed as nasopharyngeal carcinoma (WHO classification is I, II and III);\n2. MRI scan was performed at the initial diagnosis (before anti-tumor treatment), and transverse and coronal MRI images before treatment were available, including T1-weighted, T2-weighted and T1-enhanced scanning sequences.\n3. PET\u002FCT scan was performed at the initial diagnosis (before anti-tumor treatment)\n4. When MRI and PET\u002FCT were inconsistent in judging the benign or malignant nature of lymph nodes, the patient agreed to undergo cervical lymph node puncture and pathological examination.\n\nExclusion Criteria:\n\n1. The patient has undergone cervical lymph node radiotherapy for any reason\n2. Combined with other malignant tumors",{"count":247,"type":21},"(I) AI Model for Diagnosing Lymph Node Metastasis We developed an AI model to help diagnose whether a single lymph node in nasopharyngeal cancer has spread. The model uses MRI images of the lymph node and the area around it. It includes: 1.Automatically identifying the lymph nodes and the primary tumor. 2.Analyzing MRI images of the lymph node and surrounding area. 3.Using MRI scans before and after chemotherapy to track changes in the lymph node.\n\n(II) AI Model for Predicting Lymph Node Metastasis We created an AI model that predicts whether a lymph node in a specific area has cancer. This model uses a combination of the primary tumor's pathology and MRI images of both the tumor and lymph node. It also tracks changes in the lymph node over time. The model includes: 1.Analyzing the tumor's pathology to identify specific lymphatic structures. 2.Using MRI scans to predict the likelihood of metastasis in a single lymph node. 3.Examining MRI scans before and after chemotherapy to help determine if the lymph node has metastasized.\n\n(III) Verifying and Analyzing the Benefits of the AI Model We are testing the AI model to see how well it works and its potential benefits, including: 1.Checking if the AI can correct past diagnoses of recurrent lymph nodes in nasopharyngeal cancer, which could help guide treatment plans for radiotherapy. 2.Testing the model using biopsy results from head and neck cancer patients to see if it can accurately detect negative lymph nodes. 3.Running clinical trials to test the AI model's safety and effectiveness in guiding radiation treatment for upper neck and single lymph node areas in nasopharyngeal cancer. 4.Analyzing the economic benefits of using the AI model in radiation treatment for nasopharyngeal cancer.",[321,27],"Nasopharyngeal Cancinoma (NPC)",[323,324,325,326,327],"Nasopharyngeal carcinoma","Cervical lymph node metastasis","MRI","pathology","Artificial Intelligence Diagnostic Model","2025-02-14",{"date":330,"type":33},"2025-02-17",{"date":332,"type":33},"2024-11-19",{"date":334,"type":21},"2026-09-01",{"name":336,"class":40},"Sun Yat-sen University",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":84,"minAge":4,"maxAge":4,"enrollmentInfo":344,"targetDuration":345,"studyType":22,"phases":4,"briefSummary":346,"conditions":347,"keywords":348,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100569500","axillary-lns-evalution-in-breast-cancer-by-multimodal-us-100569500","NCT06695052","Axillary LNs Evalution in Breast Cancer by Multimodal Us","\"Axillary Nodal Evaluation in Breast Cancer by Multimodal US\"","Inclusion Criteria:\n\n\\- Patients with primary breast cancer (BrCa) and axillary lymph nodes (ALNs) referred to the Department of Diagnostic Radiology for pre-operative assessment of presence, extent and nature of ALNs.\n\nExclusion Criteria:\n\n* Patients with secondary or recurrent Breast Ca\n* Patients exposed to loco-regional radio- or chemotherapy\n* Patients with previous axilla surgery\n* ± Patients with confirmed metastatic tumor to bone, liver and\u002For lungs\n* Patients who deny or refuse to participate in the study",{"count":146,"type":21},"1 Year","The present study is designed to evaluate the role of simultaneous multi-modal sonographic tools-Ultrasound (US), Color Doppler Ultrasound (CDU), and Ultrasound Elastography (UE)-in determining the nature (benign or malignant) of axillary lymph nodes (ALNs) in patients with primary breast cancer. It aims to compare the diagnostic indices of each modality individually against their combined performance. Specifically, the study will assess whether adding UE to conventional gray-scale US and CDU improves diagnostic accuracy.",[172,27],[349,27,350],"breast cancer","multimodal ultrasound","2024-11-17",{"date":332,"type":33},{"date":354,"type":21},"2024-11-20",{"date":356,"type":21},"2026-12-30",{"name":358,"class":40},"Assiut University",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":52,"phases":369,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":136},"100563984","neck-observation-or-elective-neck-dissection-in-ct1n0m0-oscc-100563984","NCT06623266","Neck Observation or Elective Neck Dissection in CT1N0M0 OSCC","Neck Observation Versus Selective Neck Dissection in Patients with CT1N0M0 Oral Squamous Cell Carcinoma: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Tumor site: tongue, gingiva, buccal mucosa, floor of mouth, hard palate, retromolar eara\n* Clinical stage is cT1N0M0 (AJCC 8th edition)\n* Pathological diagnosis of squamous cell carcinoma\n* Sign the informed consent form\n\nExclusion Criteria:\n\n* More than 2 lesions found in the oral cavity\n* Known history of malignant tumor within five years (unless the patient has undergone curative treatment and there is no disease recurrence within 5 years since the start of treatment)\n* History of unilateral or bilateral neck dissection in the past\n* History of previous head and neck radiotherapy\n* Pregnant or lactating women\n* Severe, uncontrolled infection or known HIV infection; or previous organ transplantation, stem cell or bone marrow transplantation\n* Participated in other clinical studies within 30 days before enrollment\n* Other circumstances that the researcher considers unsuitable for participation in the study","75 Years",{"count":368,"type":21},300,[54],"To evaluate the clinical outcomes of 2-year lymph node metastasis rate, disease-free survival, overall survival, and health-related quality of life in the patients with cT1N0M0 oral squamous cell carcinoma, who receive primary lesion resection combined with elective neck dissection or primary lesion resection only.",[372,27],"Oral Cancer",[374,375,376,377,378],"Oral squamous cell carcinoma","Early stage","Neck dissection","Neck observation","Lymph node metastasis rate","2024-11-12",{"date":381,"type":33},"2024-11-14",{"date":383,"type":33},"2024-09-26",{"date":385,"type":21},"2028-09-30",{"name":387,"class":40},"Huashan Hospital",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":366,"enrollmentInfo":394,"targetDuration":396,"studyType":22,"phases":4,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":4},"100553443","evaluation-of-axillary-lymph-node-metastasis-status-of-breast-cancer-based-on-pathological-images-and-virtual-staining-100553443","NCT06486155","Evaluation of Axillary Lymph Node Metastasis Status of Breast Cancer Based on Pathological Images and Virtual Staining","Inclusion Criteria:\n\nPart 1:\n\nFemale patients aged 18-75 with breast cancer; Undergoing surgical excision of breast cancer and sentinel lymph node biopsy\u002Faxillary lymph node dissection; Lymph nodes with clear postoperative paraffin pathological results.\n\nPart 2:\n\nPatients aged 18-75 with one of the following cancers: thyroid, lung, esophagus, stomach, colorectal, prostate, bladder, or cervix; Undergoing surgical resection of lymph nodes; Lymph nodes with clear postoperative paraffin pathological results.\n\nPart 3:\n\nFemale patients aged 18-75 with breast cancer; Undergoing surgical excision of breast cancer and sentinel lymph node biopsy; Sentinel lymph nodes with clear postoperative paraffin pathological results.\n\nExclusion Criteria:\n\nPart 1 \u002F Part 2:\n\nLymph node diagnosis is missing; Absence of lymph node component in the slice.\n\nPart 3:\n\nSentinel lymph node diagnosis is missing; Absence of lymph node component in the frozen slice.",{"count":395,"type":21},2200,"5 Years","The goal of this observational study is to develop an artificial intelligence model to transform unstained lymph node tissue slice images directly into stained images. The main questions it aims to answer are:\n\nCan the virtual staining model generate hematoxylin and eosin (H\\&E) and immunohistochemistry (IHC) images suitable for clinical diagnosis from unstained paraffin-embedded lymph node slice images, including those from breast axillary lymph nodes and other tumor lymph nodes?\n\nCan the virtual staining model generate H\\&E and IHC images suitable for clinical diagnosis from unstained frozen sentinel lymph node slice images from breast cancer patients?\n\nResearchers will retrospectively collect paraffin-embedded lymph node slices from tumor patients and prospectively collect frozen sentinel lymph node slices from breast cancer patients.",[399,27,172,400],"Virtual Staining","Digital Pathology","2024-08-10",{"date":403,"type":33},"2024-08-13",{"date":405,"type":21},"2024-08",{"date":407,"type":21},"2025-12",{"name":409,"class":40},"Yunnan Cancer Hospital",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":366,"enrollmentInfo":417,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":424,"leadSponsor":425,"locationsCount":4},"100555334","prediction-of-non-sentinel-lymph-node-metastatic-status-of-breast-cancer-based-on-pathology-mri-images-100555334","NCT06510738","Prediction of Non-sentinel Lymph Node Metastatic Status of Breast Cancer Based on Pathology-MRI Images","Prediction of Non-sentinel Lymph Node Metastatic Status of Breast Cancer Based on Pathology-MRI Images and Artificial Intelligence","Inclusion Criteria:\n\n1. Patients with primary breast cancer\n2. Positive sentinel lymph node biopsy and axillary lymph node dissection.\n3. No neoadjuvant chemotherapy, radiotherapy or ablation prior to surgery.\n4. MRI within 3 weeks prior to surgery.\n\nExclusion Criteria:\n\n1. recurrent breast cancer or history of surgery or radiation therapy in the axilla\n2. Inflammatory breast cancer\n3. Bilateral breast cancer or metastatic breast cancer\n4. previous or current history of other malignant tumors\n5. Sentinel lymph node count \\> 5",{"count":418,"type":21},700,"The goal of this observational study is to develop an artificial intelligence model based on pathology and magnetic resonance imaging (MRI) images to predict the metastatic status of non-sentinel lymph nodes in patients with breast cancer sentinel lymph node metastasis. The main questions it aims to answer are:\n\nCan an artificial intelligence model based on MRI images of breast cancer patients predict the non-sentinel lymph node metastatic status in patients with breast cancer sentinel lymph node metastasis?\n\nCan an artificial intelligence model based on intraoperative frozen section images of sentinel lymph nodes in breast cancer patients predict the non-sentinel lymph node metastasis status in patients with sentinel lymph node metastasis from breast cancer?\n\nCan artificial intelligence models based on preoperative MRI and intraoperative frozen section images of sentinel lymph nodes in breast cancer patients predict the non-sentinel lymph node metastatic status in patients with sentinel lymph node metastasis from breast cancer?\n\nResearchers will retrospectively and prospectively collect preoperative MRI and intraoperative sentinel lymph node section images from breast cancer patients.",[172,421,27,400],"Artificial Intelligence",{"date":403,"type":33},{"date":405,"type":21},{"date":407,"type":21},{"name":409,"class":40},{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":366,"enrollmentInfo":432,"targetDuration":4,"studyType":52,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":136},"100552100","improvements-in-thyroid-tumor-surgery-and-the-prognosis-diagnosis-recurrence-and-metastasis-of-patients-100552100","NCT06468696","Improvements in Thyroid Tumor Surgery and the Prognosis, Diagnosis, Recurrence and Metastasis of Patients","Inclusion Criteria:\n\n1. Perform transthoracic endoscopic thyroidectomy via breast approach;\n2. Postoperative pathology confirms benign or malignant thyroid tumors;\n3. Preoperative thyroid ultrasound or cervical CT suggests no extrathyroidal invasion or distant metastasis of the tumor;\n4. No contraindications for general anesthesia;\n5. Patients with cosmetic requirements.\n\nExclusion Criteria:\n\n1. Underwent transthoracic endoscopic thyroidectomy;\n2. Postoperative pathology confirmed as benign or malignant thyroid tumors;\n3. Preoperative thyroid ultrasound or neck CT suggested no extraglandular invasion or distant metastasis of the tumor;\n4. No contraindications to general anesthesia;\n5. Patients with cosmetic demands.",{"count":433,"type":21},170,[54],"The objective of this research is to investigate the clinical outcomes of modified surgical techniques such as omitting the cervical linea alba suture in transthoracic endoscopic thyroidectomy. Furthermore, the study requires the collection of normal thyroid tissues, benign and malignant thyroid tumors, and lymph nodes to further clarify the mechanisms associated with the initiation, progression, metastasis, and recurrence of thyroid cancer.",[437,27,438],"Papillary Thyroid Cancer","Carcinogenesis","2024-06-20",{"date":441,"type":33},"2024-06-21",{"date":443,"type":33},"2023-04-01",{"date":445,"type":21},"2026-01-01",{"name":447,"class":40},"Second Affiliated Hospital of Xi'an Jiaotong University",{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":49,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":467,"locationsCount":136},"100550578","development-of-an-imaging-prediction-model-for-pelvic-lymph-node-metastasis-of-cervical-cancer-using-artificial-intelligence-techniques-100550578","NCT06448897","Development of an Imaging Prediction Model for Pelvic Lymph Node Metastasis of Cervical Cancer Using Artificial Intelligence Techniques.","Inclusion criteria:\n\n1. patients with preoperative diagnosis of invasive cervical cancer stage I-III, with any type of pathology, and patients who underwent radical\u002Fmodified radical cervical cancer surgery + pelvic lymph node dissection in our hospital.\n2. Age ≥18 years old and ≤80 years old\n3. patients with complete preoperative pelvic MRI images and postoperative pathology and clinical data in our hospital\n\nExclusion criteria:\n\n1. Patients during pregnancy or breastfeeding, patients within 42 days of abortion\n2. Patients who have received neoadjuvant chemotherapy or radiotherapy before surgery for this previous cervical cancer\n3. Patients with other malignant tumors within 5 years\n4. Combination of other underlying diseases that may lead to enlarged pelvic lymph nodes\n5. Imaging report more than 1 month prior to surgery\n6. Poor image quality and unrecognizable",{"count":455,"type":21},4000,"This study is a retrospective exploratory trial conducted at a single center, aiming to develop and validate a preoperative lymphatic metastasis model for cervical cancer using artificial intelligence deep learning. The model is trained using preoperative imaging and postoperative pathological findings of cervical cancer patients, with the goal of enhancing the accuracy of lymphatic metastasis prediction through preoperative imaging and offering insights for treatment decisions.",[458,27,421],"Cervical Cancer",[458,27,460],"Artificial Interlligence","2024-06-03",{"date":463,"type":33},"2024-06-07",{"date":465,"type":33},"2024-02-01",{"date":407,"type":21},{"name":468,"class":40},"Obstetrics & Gynecology Hospital of Fudan University",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":366,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":489,"locationsCount":491},"100526502","study-on-the-no253-lymph-node-metastasis-patterns-in-left-sided-colon-and-rectal-cancer-100526502","NCT06135571","Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer","Real World Registry Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer","Inclusion Criteria:\n\n1. Age: 18-75 years;\n2. Underwent laparoscopic left hemicolectomy, sigmoid colectomy, or rectal cancer radical surgery.\n3. Postoperative pathology confirmed as adenocarcinoma.\n4. No evidence of distant metastasis.\n\nExclusion Criteria:\n\n1. Previous history of malignant colorectal tumors.\n2. Patients who have undergone multiple abdominal-pelvic surgeries.\n3. Patients undergoing emergency surgery due to complications such as intestinal obstruction, intestinal perforation, or intestinal bleeding.\n4. Surgery did not achieve R0 resection.\n5. Patients with concurrent other malignant tumors or multiple primary colorectal cancers.\n6. Patients unwilling to sign an informed consent or follow the study protocol for follow-up.",{"count":20,"type":21},"The goal of this observational study is to learn about the the pattern of metastasis of the No.253 lymph node in colorectal cancer. The main questions it aims to answer are: 1. What are the risk factors for metastasis to the No.253 lymph node? 2.What is the prognosis for patients with metastasis to the No.253 lymph node? Patients with descending colon cancer, sigmoid colon cancer, and rectal cancer who undergo curative surgery with dissection of the No.253 lymph node are included in this study",[479,27],"Colorectal Cancer",[481,124,482],"Left-sided colorectal cancer","No.253 lymph node","2023-11-16",{"date":485,"type":33},"2023-11-18",{"date":487,"type":33},"2023-09-01",{"date":334,"type":21},{"name":490,"class":40},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",4,{"id":493,"slug":494,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":500,"conditions":501,"keywords":507,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":136},"100509828","observational-study-of-viral-biomarkers-and-micrornas-in-tumors-orofarynx-and-occult-tumors-positive-for-papilloma-virus-100509828","NCT05918510","Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus","Inclusion Criteria:\n\n* Squamous cell carcinomas of the oropharynx and occult neoplasms with lymph node metastases laterocervical cytologically positive for squamous cell carcinoma treated with TORS or RT or RT\u002FCT\n* Age \\> 18 years\n* ECOG performance status \\\u003C\\_ 2\n* Ability to follow study procedures and complete questionnaires\n* Signature of informed consent\n\nExclusion Criteria:\n\n* Presence of distant metastases at the time of diagnosis\n* Previous cancer of the head and neck district\n* Second tumor in therapy or follow-up for less than 5 years",{"count":499,"type":21},142,"Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids of these patients, may have important prognostic and diagnostic value not only in HPV-related OPSCCs but also in HPV+ occult T. Accordingly, this study aims to aim to better characterize their potential as biomarkers and to detect the possibility of their their use to implement the sensitivity and specificity of radiological methodologies (PET-CT and MRI), already in use in clinical practice, for monitoring disease progression in this specific subgroup. Finally, by using the collected material to generate organoids and Patient Derived Xenograft (PDX), the study also aims to identify possible new molecular drugs, which could solve the problem of resistance to radiochemotherapy.",[502,503,504,505,27,506],"Squamous Cell Carcinoma of the Oropharynx","Carcinomas of Unknown Primary Site","High-risk Human Papillomavirus Infection","Liquid Biopsy","Occult Tumor of the Head and Neck Area",[508,509,510,511],"Oropharyngeal Tumor","Occult Cancer","HPV Infection","head-neck area","2023-10-06",{"date":514,"type":33},"2023-10-10",{"date":516,"type":33},"2022-04-04",{"date":518,"type":21},"2029-04-04",{"name":520,"class":40},"Regina Elena Cancer Institute",{"id":522,"slug":523,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":52,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":238},"100521153","para-aortic-lymph-node-metastasis-in-resectable-pancreatic-cancer-100521153","NCT06065891","Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer","Prevalence and Consequences of Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer: a Prospective Population Based Multicenter Study. The PALN Study","PALN","Inclusion Criteria:\n\nResectable suspected periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020)\n\nBorderline resectable periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020)\n\nAge \\>18 years\n\nWritten patient consent\n\nExclusion Criteria:\n\nContraindication for a radical resection procedure\n\nUnresectable tumor (NCCN guidelines 2020) or metastatic disease (lgll station 16 not included)\n\nMental or organic disorders which could interfere with giving informed consent or receiving treatments",{"count":368,"type":21},[54],"Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) are the final nodes for periampullary cancers before the cancer cells enter the systemic lymphatic circulation. Some consider these nodes to be regional lymph nodes and dissect them as a part of a routine lymphadenectomy for pancreatic cancer. Others argue that metastases to these nodes represent systemic disease and recommend that radical surgery including extended lymphadenectomy should be abandoned.\n\nThe aim of this study is to define the incidence and clinical consequences of PALN metastasis in patients submitted to a tentative curative resection for carcinoma of the head of the pancreas by systematically resecting paraaortic lymph nodes.\n\nPrimary outcome\n\n1\\) To determine incidence of PALN metastasis in patients submitted to a tentative curative resection\n\nSecondary outcomes\n\n1. To determine prognosis of patients with PALN metastasis after a curative resection\n2. To determine incidence of metastasis in reginal lymph nodes in patients submitted to a tentative curative resection.\n3. To determine prognosis of patients with metastasis in regional lymph nodes in patients submitted to a tentative curative resection.\n4. To address the question of how to optimize the frozen section analyses of PALN as related to the final pathology report.\n\n300 patients are planned to be included in the trial.",[533,534,27],"Pancreas Cancer","Pancreas Adenocarcinoma","2023-09-26",{"date":537,"type":33},"2023-10-04",{"date":539,"type":33},"2023-09-05",{"date":541,"type":21},"2028-09-05",{"name":543,"class":40},"Jon Unosson",{"id":545,"slug":546,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":552,"conditions":553,"keywords":554,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":136},"100516208","serum-and-tissue-metabolite-based-prediction-of-sentinel-lymph-node-metastasis-in-breast-cancer-100516208","NCT06001528","Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast Cancer","Inclusion Criteria:\n\n* Pathological diagnosis of breast cancer\n* No preoperative therapy including chemotherapy or endocrine therapy\n* No distant metastasis\n* Underwent mastectomy or breast-conserving surgery with sentinel lymph node biopsy\n* Agreed to provide preoperative peripheral blood samples\n* Had access to imaging, pathological and follow-up data for preoperative and postoperative evaluation of the disease\n\nExclusion Criteria:\n\n* Neoadjuvant therapy\n* Presence of distant metastasis at time of diagnosis\n* Primary malignancies other than breast cancer\n* Bilateral breast cancer or previous contralateral breast cancer\n* Undergo modified radical surgery for breast cancer without sentinel lymph node biopsy\n* Incomplete pathological data and follow-up data\n* Pregnancy and other conditions determined by the investigator to be ineligible for inclusion in the study",{"count":551,"type":21},2400,"Breast cancer is a malignant tumor with the highest morbidity and mortality among women worldwide. Accurate staging of axillary lymph nodes is critical for metastatic assessment and decisions regarding treatment modalities in breast cancer patient. Among patients who underwent sentinel lymph node biopsy, about 70 % of the patients had negative pathological results and in other words, these 70 % of the patients received unnecessary surgery. At present, imaging and pathological diagnosis is the main measure of lymph node metastasis in breast cancer. However, limitations remained. Artificial intelligence, including deep learning and machine learning algorithms, has emerged as a possible technique, which can make a more accuracy prediction through machine-based collection, learning and processing of previous information, especially in radiology and pathology-based diagnosis. With the intensification of the concept of precision medicine and the development of non-invasive technology, the investigators intend to use the artificial intelligence technology to develop a serum and tissue-based predictive model for sentinel lymph node metastasis diagnosis combined with imaging and pathological information, providing specific, efficient and non-invasive biological indicators for the monitoring and early intervention of lymph node metastasis in patient with breast cancer. Therefore, the investigators retrospectively include serum samples from early breast cancer patients undergoing sentinel lymph node biopsy, including a discovery cohort and a modeling cohort. Metabolites were detected and screened in the discovery cohort and then as the target metabolites for targeted detection in the modeling cohort. Combined with preoperative imaging and pathological information, a prediction model of breast cancer sentinel lymph node metastasis based on serum metabolites would be established. Subsequently, multi-center breast cancer patients will prospectively be included to verify the accuracy and stability of the model.",[172,27],[349,555,556,557],"sentinel lymph node metastasis","metabolic reprogramming","artificial intelligence",{"date":559,"type":33},"2023-09-28",{"date":561,"type":33},"2021-01-01",{"date":563,"type":21},"2026-08-31",{"name":565,"class":40},"Shantou Central Hospital",{"id":567,"slug":568,"hasResults":11,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":573,"targetDuration":4,"studyType":52,"phases":575,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":583,"leadSponsor":585,"locationsCount":136},"100518492","phase-3-selective-lymph-node-dissection-for-ct1n0m0-invasive-nsclc-with-ctr05-located-in-the-apical-segment-ectop-1018-100518492","NCT06031246","Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)","Selective Lymph Node Dissection for cT1N0M0 Invasive Non-small Cell Lung Cancer With CTR>0.5 Located in the Apical Segment: a Single-arm, Multi-center, Phase III Trial","Inclusion Criteria:\n\n1. Patients who sign the informed consent form and are willing to complete the study according to the plan;\n2. Aged from 18 to 80 years old;\n3. ECOG equals 0 or 1;\n4. Not receiving lung cancer surgery before;\n5. Resectable peripheral cT1N0M0 tumors with CTR\\>0.5 located in the apical segment;\n6. Non-lepidic predominant invasive NSCLC dignosed by frozen section;\n7. Not receiving chemotherapy or radiotherapy before.\n\nExclusion Criteria:\n\n1. Not cT1N0M0;\n2. Nodules not located in the apical segment or CTR≤0.5;\n3. Pre-invasive lung adenocarcinoma, lepidic predominant adenocarcinoma, or not lung adenocarcinoma diagnosed cytologically or pathologically;\n4. Receiving lung cancer surgery before;\n5. Receiving radiotherapy or chemotherapy.",{"count":574,"type":21},634,[88],"This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1018. The goal of this clinical trial is to confirm the theraputic effect of selective lymph node dissection for cT1N0M0 invasive non-small cell lung cancer with CTR\\>0.5 located in the apical segment. The main questions it aims to answer are:\n\nThe 5-year overall survival of patients having cT1N0M0 invasive non-small cell lung cancer with CTR\\>0.5 located in the apical segment; The post-operative lymph node metastasis and recurrence-free survival. Participants will receive selective lymph node dissection as the surgical procedure.",[578,27],"Lung Adenocarcinoma","2023-09-04",{"date":581,"type":33},"2023-09-11",{"date":443,"type":33},{"date":584,"type":21},"2030-12-31",{"name":586,"class":40},"Fudan University",{"id":588,"slug":589,"hasResults":11,"nctId":590,"briefTitle":591,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":595,"conditions":596,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":136},"100485093","role-of-intrapulmonary-lymph-nodes-in-patients-with-nsclc-and-visceral-pleural-invasion-100485093","NCT05596578","Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion","Inclusion Criteria:\n\n* Anatomical resection for NSCLC \\\u003C3 cm (lobectomy, bilobectomy, segmentectomy)\n* Samples from the intrapulmonary stations 12, 13, and 14 lymph nodes\n* Resection of lymphnodes station 10 and 11 during hilar separation.\n* R0 resection\n\nExclusion Criteria:\n\n* Prior or synchronous lung cancer\n* pN2\n* Pneumonectomy\n* R1\u002FR2 resection\n* M1\n* Neoadjuvant treatment",{"count":594,"type":21},958,"Background: Lung cancer is the leading cause of cancer related death worldwide. More than 80% of all lung tumors are Non-Small Cell Lung Cancers (NSCLC). Lymph node staging has a prognostic value and is crucial to establish the optimal treatment strategy in individual patients. It remains unknown whether dissecting the intrapulmonary lymph nodes (stations 13 and 14) is necessary for accurate staging and prognostication. Although suggested by several guidelines, these peripheral lymph nodes are not routinely examined in clinical routine for several reasons. Moreover, the prognostic significance of the visceral pleural invasion is controversial. Some studies showed a negative impact on OS and DFS in patients with histologic proved visceral pleura invasion.\n\nThe mechanism to explain this negative effect is not fully understood. Given that the visceral pleura is very rich in lymphatic vessels, with an intercommunicating \"network\" arranged over the lung surface and penetrating into the lung parenchyma to join the bronchial lymph vessels with drainage to the various hilar nodes, we assume that the worse OS and DFS observed in these patients could be explained with the presence of metastatic lymph nodes (Station 13-14) that are not routinely examined. Methods: This is a prospective, multicenter study based on ad-hoc created prospectively database. The incidence of N1 lymph node metastasis overall and the incidence of metastasis to the different lymph node stations (Hilar 10\u002F11, Lobar 12, Sublobar 13\u002F14) will be calculated by dividing the number of the respective events by the patient years separately. To investigate the association between visceral pleural invasion and the presence of metastatic lymph nodes univariate and multivariate logistic regression models will be fitted to the data.\n\nDiscussion: The primary outcome is to investigate the incidence of N1 metastases (especially stations 12,13,14) and his relationship with visceral pleural invasion. The secondary outcomes is to evaluate the impact of N1 metastases and\u002For visceral pleural invasion on long-term outcomes (OS and DFS) along with incidence and pattern of recurrence. DFS is defined as the time of surgical intervention to tumor recurrence or death, and OS is defined as the time of surgical intervention to death",[120,27],"2023-01-05",{"date":599,"type":33},"2023-01-09",{"date":601,"type":33},"2023-01-01",{"date":603,"type":21},"2029-12-31",{"name":605,"class":40},"Luzerner Kantonsspital"]